Eli Lilly reaps rewards of Novo acquisition

By acquiring Dicerna, Novo Nordisk has sent DKK 700m (USD 107m) into the hands of its competitor Eli Lilly in the form of returns on shares in the acquired company, which Lilly co-owns.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by marketwire, translated by daniel pedersen

On Thursday, Novo Nordisk annouced that it is acquiring the US-based biotech company Dicerna for USD 3.3bn.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading